Rhenovia Pharma secures Series B
Rhenovia Pharma has raised EUR 540,000 ($738,000) from its historical shareholders in a second round of funding. Founded in 2007, the business is a biotechnology company specialized in the application of biosimulation to the research and development of new medicinal products.
12 February 2014•3 mins read
